905722070

• GAAP net income was $371.4 million ($13.85 per diluted share) versus $317.8 million ($11.67 per diluted share) in Q2 2025, driven largely by a change in fair market value of its Sartorius AG investment.
• Non-GAAP net income was $70.2 million ($2.62 per diluted share) versus $71.0 million ($2.61 per diluted share) in Q2 2025.
• The company initiated a restructuring plan on July 31, 2026, expecting pre-tax charges of approximately $80 to $90 million, with completion expected by end of fiscal year 2027.
• Full-year 2026 outlook reaffirmed: non-GAAP currency-neutral revenue expected to decline approximately 3.0% to grow approximately 0.5%, with non-GAAP operating margin of approximately 10.0% to 12.0%.

2.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• GAAP net loss was $527.1 million, or $19.55 per diluted share, versus net income of $64.0 million, or $2.29 per share, in Q1 2025.
• Non-GAAP net income was $50.9 million, or $1.89 per diluted share, compared to $71.0 million, or $2.54 per share, in the prior-year quarter.
• The company updated its full-year 2026 outlook, now expecting non-GAAP currency-neutral revenue to decline approximately 3.0% to grow 0.5%, and non-GAAP operating margin of approximately 10.0% to 12.0%.
• The net loss was substantially driven by a $738.2 million loss from the change in fair market value of equity securities, including its investment in Sartorius AG.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• At the April 21, 2026 annual meeting, stockholders approved the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, which increases reserved shares by 335,000 and extends the plan to March 18, 2036.
• Stockholders ratified KPMG LLP as independent auditors for fiscal year 2026.
• The non-binding advisory vote on executive compensation was approved.
• A stockholder proposal regarding dual class capital structure was not approved.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• The update reflects Sartorius AG's financial results for the year ended December 31, 2025, disclosed by Sartorius on February 16, 2026.
• Sartorius reported sales revenue of €3,538.1 million, EBIT of €542.6 million, and net profit of €230.4 million for 2025.
• Sartorius's total assets were €9,717.3 million, with equity of €3,867.2 million as of December 31, 2025.
• The filing was made under Item 7.01 Regulation FD Disclosure, and Bio-Rad disclaims responsibility for errors in Sartorius's public data.

7.01 Regulation FD Disclosure

• GAAP net income for Q4 2025 was $720.0M ($26.65 diluted EPS) vs. a net loss of $715.8M in Q4 2024.
• Full-year 2025 revenue was $2,583.2M, up 0.7% from $2,566.5M in 2024; currency-neutral revenue was essentially flat.
• Full-year 2025 GAAP net income was $759.9M ($27.85 diluted EPS) vs. a net loss of $1,844.2M in 2024.
• For 2026, Bio-Rad expects non-GAAP currency-neutral revenue growth of 0.5% to 1.5% and non-GAAP operating margin of 12.0% to 12.5%.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• GAAP net loss was $341.9 million, or $12.70 per diluted share, versus net income of $653.2 million, or $23.34 per share, in Q3 2024, primarily due to a change in fair value of its Sartorius AG investment.
• Non-GAAP net income was $60.8 million, or $2.26 per diluted share, compared to $56.3 million, or $2.02 per share, in the prior-year quarter.
• Life Science segment sales were $261.8 million (up 0.3% as reported, down 1.5% currency-neutral); Clinical Diagnostics sales were $391.2 million (up 0.6% as reported, down 1.8% currency-neutral).
• For full-year 2025, Bio-Rad maintains its outlook for non-GAAP currency-neutral revenue growth of approximately 0 to 1.0% and a non-GAAP operating margin of approximately 12.0% to 13.0%.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Schwartz co-founded Bio-Rad in 1952 in Berkeley, California, with her husband David Schwartz.
• She was instrumental in developing Bio-Rad's first thyroid function test kit in the 1960s, marking the company's entry into clinical diagnostics.
• Schwartz remained an active Board member until 2022.
• The disclosure was made under Item 7.01 Regulation FD and included a press release as Exhibit 99.1.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The webinar featured a presentation and Q&A session hosted by President and COO Jon DiVincenzo and CFO Roop K. Lakkaraju.
• The accompanying slide presentation was posted on Bio-Rad's Investor Relations website and attached as Exhibit 99.1 to the Form 8-K.
• The presentation highlights Bio-Rad's ddPCR platforms, assay catalog of over 490,000 assays, and growth drivers in the absolute quantitation segment.
• The disclosure was made under Item 7.01 Regulation FD and is not deemed filed for SEC purposes.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits